Developing novel complement activation assays for application in basic and clinical research
Studying the cross-talk between complement and TLRs, in particular to the co-receptor CD14
Investigating the effect on inflammation by inhibiting complement activation and CD14 using human whole blood in vitro models and in vivo animal models of human diseases
Studying the “Thromboinflammation” and new complex whole blood models to reveal cross-talk between biological systems ex vivo
Studying complement activation in patients with diseases being tentative candidates for future complement intervention
Develop tools for evaluation of the effect of complement therapy in the clinic
Recent publications
Hovland A, Retterstøl K, Mollnes TE, Halvorsen B, Aukrust P, Lappegård KT(2020) Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential? Scand Cardiovasc J, 1-6(in press) DOI 10.1080/14017431.2020.1775878, PubMed 32500743
Berg LK, Goll R, Fagerli E, Ludviksen JK, Fure H, Moen OS, Sørbye SW, Mollnes TE, Florholmen J(2020) Intestinal inflammatory profile shows increase in a diversity of biomarkers in irritable bowel syndrome Scand J Gastroenterol, 55(5), 537-542 DOI 10.1080/00365521.2020.1754455, PubMed 32329383
Chaban V, Clarke GJB, Skandsen T, Islam R, Einarsen CE, Vik A, Damås JK, Mollnes TE, Håberg AK, Pischke SE(2020) Systemic Inflammation Persists the First Year after Mild Traumatic Brain Injury: Results from the Prospective Trondheim Mild Traumatic Brain Injury Study J Neurotrauma DOI 10.1089/neu.2019.6963, PubMed 32326805